Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS
5.1 CONCLUSION
6 REGULATIONS OF THE NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING OVARIAN CANCER AWARENESS
7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES
7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR
7.1.4 IMPROVED IMAGING TECHNIQUES
7.2 RESTRAINS
7.2.1 HIGH COST OF DIAGNOSIS
7.2.2 ADVERSE EFFECTS OF THE TREATMENT
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED PROFESSIONALS
8 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 KITS AND REAGENTS
9 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 BLOOD MARKERS TESTING
9.3 MEDICAL IMAGING TEST
9.4 BIOPSY TEST
9.5 GENETIC TESTING
10 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 EPITHELIAL TUMOR
10.3 GERM CELL
10.4 STROMAL CELL TUMOR
11 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 CANCER DIAGNOSTIC CENTERS
11.3 HOSPITAL LABORATORIES
11.4 RESEARCH INSTITUTES
11.5 OTHERS
12 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F. HOFFMANN-LA ROCHE LTD
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 TOSOH INDIA PVT. LTD.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION (2022)
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 QUEST DIAGNOSTICS INCORPORATED (2022)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 THERMO FISHER SCIENTIFIC INC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABCAM PLC (2022)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 1.7.4 RECENT DEVELOPMENT
15.8 BIOSUPPLY LTD
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RADBIO LABORATORIES
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOVISION INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOGENIX INC. PVT. LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 BOSTER BIOLOGICAL TECHNOLOGY
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 FOUNDATION MEDICINE
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 FUJIREBIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GENWAY BIOTECH
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INEX INNOVATIVE PRIVATE LIMITED
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 LCM GENETIC SRL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 LIFESPAN BIOSCIENCES, INC
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 MP BIOMEDICALS
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 MONOBIND INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 MYRIAD GENETICS, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 NGENEBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENTS
15.23 R&D SYSTEMS, INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 SIEMENS MEDICAL SOLUTIONS
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION)
TABLE 2 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 24 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 25 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 26 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 29 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 30 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 32 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 33 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 34 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 35 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030
FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022
FIGURE 19 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 35 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
